Center for Inquiry reiterates its criticism of homeopathy and calls on FDA to step up vetting of US-marketed homeopathic products.
The Center for Inquiry encourages FDA to look at the Federal Trade Commission enforcement policy requiring disclaimers for OTC homeopathic drugs' unsubstantiated claims as "the right decision to hold manufacturers accountable."
In a Nov. 16 statement on the FTC policy published Nov
Michael De Dora, CFI's public policy director, said homeopathic marketers make "absolutely baseless assertions" about homeopathy, which the center
Decision in AstraZeneca’s lawsuit against the Health and Human Services Department is a precedent-setting victory for the government and a blow to manufacturer efforts to block the price negotiation program.
Advisory committee for Capricor’s deriamocel planned, regenerative medicine advanced therapy designations proliferate for osteoarthritis, and the ranks of dual RMAT/breakthrough therapy designation holders grow.
Pink Sheet editors discuss the appointment of Vinay Prasad as the new director of the Center for Biologics Evaluation and Research and revelations that FDA layoffs now are hindering development of guidance documents.
Agency staff once again have access to the Lexis-Nexis legal and news database, but are still waiting for access to journals, and laid off librarians have not been reinstated.
Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.
President Trump's ongoing interest in the policy, which would ensure the US government pays no more for prescription drugs than the lowest price available in comparable countries, continues to gain attention.
HHS Secretary Robert F. Kennedy Jr. regularly decries the “conflicts of interest” he believes abound in advisory committees, but his concerns, as well as a recent “policy directive” eliminating industry representatives, seem driven by a misunderstanding of the panels’ jobs.
